SGMO Sangamo Therapeutics Inc

Price (delayed)

$11.43

Market cap

$1.62B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.9

Enterprise value

$1.52B

Sector: Healthcare
Industry: Biotechnology

Highlights

SGMO's debt is down by 7% YoY
The revenue is down by 20% since the previous quarter but it is up by 15% year-on-year
The gross profit fell by 20% QoQ but it rose by 15% YoY
Sangamo Therapeutics's net income has shrunk by 60% QoQ and by 27% YoY
The EPS has dropped by 53% since the previous quarter and by 6% year-on-year

Key stats

What are the main financial stats of SGMO
Market
Shares outstanding
141.44M
Market cap
$1.62B
Enterprise value
$1.52B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.24
Price to sales (P/S)
13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.88
Earnings
Revenue
$118.19M
EBIT
-$120.65M
EBITDA
-$107.28M
Free cash flow
$155.16M
Per share
EPS
-$0.9
Free cash flow per share
$1.15
Book value per share
$3.52
Revenue per share
$0.88
TBVPS
$6.23
Balance sheet
Total assets
$938.55M
Total liabilities
$441.18M
Debt
$38.4M
Equity
$498.23M
Working capital
$516.12M
Liquidity
Debt to equity
0.08
Current ratio
4.6
Quick ratio
4.52
Net debt/EBITDA
0.88
Margins
EBITDA margin
-90.8%
Gross margin
100%
Net margin
-102.4%
Operating margin
-109.6%
Efficiency
Return on assets
-14.3%
Return on equity
-25.1%
Return on invested capital
-27%
Return on capital employed
-15.2%
Return on sales
-102.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SGMO stock price

How has the Sangamo Therapeutics stock price performed over time
Intraday
-0.44%
1 week
3.35%
1 month
-13.61%
1 year
50.59%
YTD
-26.78%
QTD
-8.78%

Financial performance

How have Sangamo Therapeutics's revenue and profit performed over time
Revenue
$118.19M
Gross profit
$118.19M
Operating income
-$129.55M
Net income
-$121M
Gross margin
100%
Net margin
-102.4%
SGMO's net margin has shrunk by 99% QoQ and by 10% YoY
SGMO's operating margin has dropped by 91% since the previous quarter and by 7% year-on-year
Sangamo Therapeutics's net income has shrunk by 60% QoQ and by 27% YoY
The operating income has plunged by 53% from the previous quarter and by 23% YoY

Growth

What is Sangamo Therapeutics's growth rate over time

Valuation

What is Sangamo Therapeutics stock price valuation
P/E
N/A
P/B
3.24
P/S
13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.88
The EPS has dropped by 53% since the previous quarter and by 6% year-on-year
The price to book (P/B) is 16% higher than the last 4 quarters average of 2.8 but 9% lower than the 5-year quarterly average of 3.6
The equity rose by 15% YoY but it fell by 4.4% QoQ
The stock's P/S is 31% below its 5-year quarterly average of 18.8 but 17% above its last 4 quarters average of 11.2
The revenue is down by 20% since the previous quarter but it is up by 15% year-on-year

Efficiency

How efficient is Sangamo Therapeutics business performance
The return on sales has dropped by 99% since the previous quarter and by 10% year-on-year
The ROE has plunged by 54% from the previous quarter and by 7% YoY
The company's return on assets fell by 46% QoQ but it rose by 7% YoY
Sangamo Therapeutics's return on invested capital has decreased by 44% QoQ and by 5% YoY

Dividends

What is SGMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SGMO.

Financial health

How did Sangamo Therapeutics financials performed over time
SGMO's total assets is 113% greater than its total liabilities
SGMO's total liabilities has surged by 115% year-on-year
SGMO's total assets is up by 47% year-on-year but it is down by 2.6% since the previous quarter
SGMO's debt is 92% lower than its equity
Sangamo Therapeutics's debt to equity has decreased by 20% YoY but it has increased by 14% QoQ
The equity rose by 15% YoY but it fell by 4.4% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.